News for NovoCure Limited (NVCR)

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brac

NovoCure remains a strong buy with robust earnings, growth in cancer treatments, and significant upside potential to Wall Street targets. Read more here.

While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NovoCure Limited (NASDAQ:NVCR) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsIngrid Goldberg - Investor RelationsBill...

NovoCure (NVCR) delivered earnings and revenue surprises of -79.41% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working t

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights an

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We recently compiled a list of the 8 Stocks on Jim Cramer's Radar. In this article, we are going to take a look at where NovoCure Limited (NASDAQ:NVCR) stands against the other stocks on Jim Cramer's...

On CNBC's

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Novocure (NVCR) surpasses revenue expectations for 2024, driven by successful launches and increased approval rates.

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Teva has been a standout, and smaller stocks such as Eco Wave and Beamr have given exceptional returns, but there have also been disappointments.

IRIDEX Corp (IRIX) experienced a significant stock movement with a 6.15% increase in its share price, reaching $1.90. The trading volume was 36,983 shares, with

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday. Shares of XPeng Inc. XPEV rose sharply during Monday's session. The c...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...